Clinical Trials Logo

Glioma clinical trials

View clinical trials related to Glioma.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05392374 No longer available - Glioma Clinical Trials

Expanded Access Use of ONC201 in a Patient With Diffuse Intrinsic Pontine Gliomas

Start date: n/a
Phase:
Study type: Expanded Access

This is an intermediate-size expanded access protocol to provide ONC201 to patients with diffuse intrinsic pontine gliomas who cannot access ONC201 through clinical trials.

NCT ID: NCT03460782 No longer available - Glioblastoma Clinical Trials

An Expanded Access Program of Ipilimumab for Patients With Glioblastomas and Gliomas

Start date: n/a
Phase:
Study type: Expanded Access

IPILIMUMAB Extended Access Program for patients who received chemotherapy and / or radiation therapy before the protocol, before or after the operation.

NCT ID: NCT03311542 No longer available - Clinical trials for Glioblastoma Multiforme

Expanded Access for Pembrolizumab (MK-3475)

Start date: n/a
Phase: N/A
Study type: Expanded Access

This is an expanded access program (EAP) for patient with Melanoma and Glioblastoma who have progressed after prior Protocol therapy including Bevacizumab, Temozolomide ( TMZ ), Ipilimumab, BRAF and MEK inhibitors. The patients whose tumors are EGFR, MET or ALK positive should first receive an EFGR or ALK inhibitor, respectively, prior to treatment with pembrolizumab.

NCT ID: NCT03134131 No longer available - Glioma Clinical Trials

Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline High Grade Gliomas

Start date: n/a
Phase:
Study type: Expanded Access

The objective of this expanded access program is to provide ONC201 to eligible patients with previously-treated glioma that exhibits the H3 K27M mutation and/or that is located in the midline region of the brain.